

Haematologica  
HAEMATOL/2016/145623  
Version 2

Efficacy and safety of second-line ponatinib after failure of a single previous tyrosine kinase inhibitor for chronic myeloid leukemia patients in chronic phase

Massimo Breccia, Elisabetta Abruzzese, Alessandra Iurlo, Antonella Gozzini, Alessandro Isidori, Domenica Gangemi, Patrizia Pregno, and Giuliana Alimena

Disclosures: Acknowledgements No funding or sponsorship for this article Conflict of interest All authors declare no conflict of interest.

Contributions: Authors contribution MB designed the study, analysed data and wrote the manuscript; EA, AG, AI, PP, AI, DG collect data; GA critically revised the paper and approved final version.